Bortezomib

Bortezomib
IUPAC ime
	[(1R)-3-metil-1-[(2S)-3-fenil-2-(pirazin-2-ilformamido)propanamido]butil]boronska kiselina
Klinički podaci
Drugs.com	Monografija
Način primene	Intravenozno
Identifikatori
CAS broj	179324-69-7
ATC kod	L01XX32 (WHO)
DrugBank	DB00188
ChEMBL	CHEMBL52717
Hemijski podaci
Formula	C19H25BN4O4
Molarna masa	384,24 g·mol−1
	SMILES O=C(N[C@H](C(=O)N[C@H](B(O)O)CC(C)C)Cc1ccccc1)c2nccnc2; ;
	InChI InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1 ; Key:GXJABQQUPOEUTA-RDJZCZTQSA-N ;

Bortezomib (originalno PS-341) je bio prvi terapeutski inihbitor proteazoma koji je testiran na ljudima. FDA je odobrila ovaj lek za tretman relapsirajuće mijelomne bolest i limfoma mantl ćelija.^[1]^[2]^[3]^[4]^[5]^[6]

Reference

^ Adams J, Kauffman M: Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest. 2004;Adams, J.; Kauffman, M. (2004). „Development of the proteasome inhibitor Velcade (Bortezomib)”. Cancer Investigation. 22 (2): 304—11. PMID 15199612. doi:10.1081/cnv-120030218.
^ Bonvini P, Zorzi E, Basso G, Rosolen A: Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma. Leukemia. Bonvini, P.; Zorzi, E.; Basso, G.; Rosolen, A. (2007 Apr). „Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma”. Leukemia. 21 (4): 838—42. PMID 17268529. doi:10.1038/sj.leu.2404528. Проверите вредност парамет(а)ра за датум: |date= (помоћ). Epub 2007 Feb 1.
^ Voorhees PM, Dees EC, O'Neil B, Orlowski RZ: The proteasome as a target for cancer therapy. Clin Cancer Res. Voorhees, P. M.; Dees, E. C.; O'Neil, B.; Orlowski, R. Z. (2003 Dec 15). „The proteasome as a target for cancer therapy”. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research. 9 (17): 6316—25. PMID 14695130. Проверите вредност парамет(а)ра за датум: |date= (помоћ)
^ Oakervee HE, Popat R, Curry N, Smith P, Morris C, Drake M, Agrawal S, Stec J, Schenkein D, Esseltine DL, Cavenagh JD: PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol. Oakervee, H. E.; Popat, R.; Curry, N.; Smith, P.; Morris, C.; Drake, M.; Agrawal, S.; Stec, J.; Schenkein, D.; Esseltine, D. L.; Cavenagh, J. D. (2005 Jun). „PAD combination therapy (PS-341/Bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma”. British Journal of Haematology. 129 (6): 755—62. PMID 15953001. doi:10.1111/j.1365-2141.2005.05519.x. Проверите вредност парамет(а)ра за датум: |date= (помоћ)
^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.
^ Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B, Hassanali M (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Res. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.

Spoljašnje veze

Bortezomib

Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).

[1] Adams J, Kauffman M: Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest. 2004;Adams, J.; Kauffman, M. (2004). „Development of the proteasome inhibitor Velcade (Bortezomib)”. Cancer Investigation. 22 (2): 304—11. PMID 15199612. doi:10.1081/cnv-120030218.

[2] Bonvini P, Zorzi E, Basso G, Rosolen A: Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma. Leukemia. Bonvini, P.; Zorzi, E.; Basso, G.; Rosolen, A. (2007 Apr). „Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma”. Leukemia. 21 (4): 838—42. PMID 17268529. doi:10.1038/sj.leu.2404528. Проверите вредност парамет(а)ра за датум: |date= (помоћ). Epub 2007 Feb 1.

[3] Voorhees PM, Dees EC, O'Neil B, Orlowski RZ: The proteasome as a target for cancer therapy. Clin Cancer Res. Voorhees, P. M.; Dees, E. C.; O'Neil, B.; Orlowski, R. Z. (2003 Dec 15). „The proteasome as a target for cancer therapy”. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research. 9 (17): 6316—25. PMID 14695130. Проверите вредност парамет(а)ра за датум: |date= (помоћ)

[4] Oakervee HE, Popat R, Curry N, Smith P, Morris C, Drake M, Agrawal S, Stec J, Schenkein D, Esseltine DL, Cavenagh JD: PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol. Oakervee, H. E.; Popat, R.; Curry, N.; Smith, P.; Morris, C.; Drake, M.; Agrawal, S.; Stec, J.; Schenkein, D.; Esseltine, D. L.; Cavenagh, J. D. (2005 Jun). „PAD combination therapy (PS-341/Bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma”. British Journal of Haematology. 129 (6): 755—62. PMID 15953001. doi:10.1111/j.1365-2141.2005.05519.x. Проверите вредност парамет(а)ра за датум: |date= (помоћ)

[5] Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.

[6] Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B, Hassanali M (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Res. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.

[1]

[2]

[3]

[4]

[5]

[6]